May 12, 2025 11:08 AM EDTUpdated 01:24 PM
R&D

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

Elizabeth Cairns

Senior biopharma journalist

The an­nu­al meet­ing of the Eu­ro­pean As­so­ci­a­tion for the Study of the Liv­er (EASL) has wrapped up in Am­s­ter­dam. This was per­haps not a vin­tage …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

A service from the Financial Times